UCAR T-cell

BIOLOGICAL4 trials

Sponsors

Tianjin Huanhu Hospital, Institute of Hematology & Blood Diseases Hospital, China, The Children's Hospital of Zhejiang University School of Medicine

Conditions

ANCA Associated Systemic VasculitisANCA-Associated Vasculitis (AAV)Autoimmune DiseasesAutoimmune EncephalitisChronic Inflammatory Demyelinating PolyradiculoneuropathyConnective Tissue Disease-Associated ThrombocytopeniaIgA Nephropathy (IgAN)Inflammatory Myopathy

Early Phase 1

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

RecruitingNCT06939166

Tianjin Huanhu HospitalAutoimmune Encephalitis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Multiple Sclerosis +2

Start: 2025-06-17End: 2027-10-31Target: 12Updated: 2025-12-15

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

RecruitingNCT07507201

The Children's Hospital of Zhejiang University School of MedicineANCA Associated Systemic Vasculitis, Autoimmune Diseases, IgA Nephropathy (IgAN) +3

Start: 2026-04-01End: 2029-12-01Target: 15Updated: 2026-04-02

Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

RecruitingNCT06941129

Institute of Hematology & Blood Diseases Hospital, ChinaANCA-Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, Inflammatory Myopathy +3

Start: 2025-02-11End: 2028-03-18Target: 12Updated: 2025-09-29

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

RecruitingNCT07305116

The Children's Hospital of Zhejiang University School of MedicineANCA Associated Systemic Vasculitis, Autoimmune Diseases, IgA Nephropathy (IgAN) +3

Start: 2025-12-01End: 2029-12-01Target: 15Updated: 2026-02-03

Related Papers

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

Blood2025-11-03

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood2025-11-03